Cardiff Oncology, Inc.
SELECTION AND TREATMENT OF CANCER WITH COMBINATION THERAPIES

Abstract:

Certain molecular characteristics of cancer cells or tumors can be indicative of their sensitivity to various combination therapies. The cancer cells or tumors exhibiting such molecular profiles, such as upregulation of genes associated with mitosis or meiosis, can be sensitive to additive and more than additive effects of combination therapies. Methods for identifying, selecting, and/or treating cancer patients whose cancer is amenable to combination therapies including an antiandrogen or androgen antagonist in combination with a Plk inhibitor are disclosed. Administration of the combination of the active agents can reduce cancer cell proliferation or viability and/or tumor burden in a subject with cancer to the same degree, or a greater degree than administering to the subject the same amount of either active agent alone.